Daily aspirin may ward off pancreatic cancer
the ONA take:
Daily intake of one low-dose aspirin over several years may be enough to lower your pancreatic cancer risk, according to a new study. The report supporting this conclusion was published online in the published online in the Cancer Epidemiology, Biomarkers & Prevention journal.
The researchers, led by lead researcher Dr. Harvey Risch, gathered data from 362 people diagnosed with pancreatic cancer and 690 with no history of pancreatic cancer. The cases observed spanned a four-year period from 2005 through 2009 and respondents were recruited from 30 Connecticut hospitals. Factors considered including when the patient began taking aspirin, history of diabetes (if any), smoking history (if any), and patient weight. For purposes of this study, a "low dose" of aspirin was quantified as anywhere from 75 milligrams to 325 milligrams. The observed reduction in pancreatic cancer risk varied, but increased the longer an individual respondent had been regularly taking aspirin; a 48-percent reduction was observed in individuals taking aspirin regularly for three years before the study, and the reduction grew to 60% for those taking aspirin for 20 years or more.
At this time the American Cancer Society has cautioned that evidence as to the cancer-preventive attributes of aspirin is limited. Although there is some connection between long-term aspirin use and lower risk of colorectal cancer, the Society does not feel current research data supports an recommendation for people to take aspirin daily for cancer prevention alone.
Aspirin and/or NSAID use may improve risk of high-grade prostate cancer
Even taking a daily aspirin for just three years lowered the chances of the deadly cancer by 48 percent, the researchers said.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|